Profile data is unavailable for this security.
About the company
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
- Revenue in USD (TTM)1.76m
- Net income in USD-153.05m
- Incorporated2017
- Employees74.00
- LocationBioXcel Therapeutics Inc555 Long Wharf DrNEW HAVEN 06511-6107United StatesUSA
- Phone+1 (203) 643-8060
- Fax+1 (302) 636-5454
- Websitehttps://www.bioxceltherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aeon Biopharma Inc | 0.00 | -485.01m | 66.12m | 10.00 | -- | -- | -- | -- | -13.04 | -13.04 | 0.00 | -5.20 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -27.67 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
| Medicinova Inc | 1.00m | -8.41m | 66.21m | 13.00 | -- | 1.11 | -- | 66.21 | -0.1714 | -0.1714 | 0.0204 | 1.22 | 0.0149 | -- | -- | 76,923.08 | -12.55 | -15.36 | -13.06 | -15.90 | -- | -- | -840.85 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
| Rallybio Corp | 0.00 | -76.28m | 66.73m | 43.00 | -- | 0.6828 | -- | -- | -1.88 | -1.88 | 0.00 | 2.36 | 0.00 | -- | -- | 0.00 | -58.30 | -- | -62.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
| Lantern Pharma Inc | 0.00 | -17.53m | 67.03m | 21.00 | -- | 1.87 | -- | -- | -1.62 | -1.62 | 0.00 | 3.32 | 0.00 | -- | -- | 0.00 | -36.82 | -28.83 | -39.63 | -30.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.93 | -- | -- | -- |
| Checkpoint Therapeutics Inc | 68.00k | -52.32m | 67.80m | 23.00 | -- | -- | -- | 997.13 | -2.37 | -2.37 | 0.0028 | -0.2872 | 0.0076 | -- | -- | 2,956.52 | -585.51 | -142.43 | -- | -342.79 | -- | -- | -76,938.23 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
| CEL-SCI Corp | 0.00 | -29.95m | 68.78m | 43.00 | -- | 4.80 | -- | -- | -0.6304 | -0.6304 | 0.00 | 0.2645 | 0.00 | -- | -- | -- | -87.78 | -70.19 | -103.56 | -78.31 | -- | -- | -- | -15,434.15 | 1.18 | -39.26 | 0.4319 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
| LAVA Therapeutics NV | 12.54m | -28.59m | 69.40m | 37.00 | -- | 1.37 | -- | 5.54 | -1.07 | -1.07 | 0.4668 | 1.93 | 0.107 | -- | 9.09 | 338,837.80 | -24.40 | -- | -28.91 | -- | 79.64 | -- | -228.02 | -- | -- | -- | 0.108 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| BioXcel Therapeutics Inc | 1.76m | -153.05m | 69.43m | 74.00 | -- | -- | -- | 39.54 | -5.18 | -5.18 | 0.0591 | -2.15 | 0.0134 | 0.6067 | 5.31 | 23,729.73 | -116.64 | -74.57 | -151.39 | -84.06 | 24.15 | -- | -8,715.72 | -32,300.74 | 2.49 | -15.67 | 3.47 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| Intensity Therapeutics Inc | 0.00 | -15.13m | 69.52m | 5.00 | -- | 7.15 | -- | -- | -1.10 | -1.10 | 0.00 | 0.709 | 0.00 | -- | -- | 0.00 | -206.66 | -- | -696.72 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
| Alpha Teknova Inc | 36.85m | -36.06m | 69.81m | 210.00 | -- | 0.8373 | -- | 1.89 | -1.05 | -1.05 | 1.05 | 2.04 | 0.2815 | 2.29 | 7.89 | 175,490.50 | -27.54 | -- | -29.30 | -- | 27.36 | -- | -97.85 | -- | 3.92 | -28.23 | 0.1365 | -- | -11.43 | -- | 22.52 | -- | -- | -- |
| Tempest Therapeutics Inc | 0.00 | -29.76m | 71.32m | 17.00 | -- | 3.46 | -- | -- | -1.76 | -1.76 | 0.00 | 0.9287 | 0.00 | -- | -- | 0.00 | -72.84 | -57.10 | -93.72 | -71.20 | -- | -- | -- | -- | -- | -141.39 | 0.3394 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
| Marinus Pharmaceuticals Inc | 28.29m | -145.34m | 71.41m | 165.00 | -- | -- | -- | 2.52 | -2.64 | -2.64 | 0.5142 | -0.2992 | 0.1554 | 0.8536 | 3.72 | 171,442.40 | -79.82 | -49.64 | -96.93 | -57.76 | 91.22 | -- | -513.80 | -518.96 | 2.93 | -13.62 | 1.29 | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
| Landos Biopharma Inc | 0.00 | -24.80m | 71.68m | 19.00 | -- | 3.09 | -- | -- | -3.99 | -3.99 | 0.00 | 7.43 | 0.00 | -- | -- | 0.00 | -61.17 | -59.84 | -70.67 | -72.15 | -- | -- | -- | -795.80 | -- | -594.02 | 0.00 | -- | -- | -- | 44.15 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 2.49m | 6.74% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 1.23m | 3.33% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.06m | 2.86% |
| Columbia Management Investment Advisers LLCas of 31 Mar 2024 | 579.16k | 1.56% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 464.91k | 1.26% |
| Geode Capital Management LLCas of 31 Mar 2024 | 457.92k | 1.24% |
| Armistice Capital LLCas of 31 Mar 2024 | 370.97k | 1.00% |
| Beacon Pointe Advisors LLCas of 31 Mar 2024 | 301.74k | 0.82% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 211.60k | 0.57% |
| Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 190.97k | 0.52% |
